Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

Author:

Tasneen Rokeya1,Mortensen Deborah S.2,Converse Paul J.1,Urbanowski Michael E.1,Upton Anna3,Fotouhi Nader3,Nuermberger Eric1ORCID,Hawryluk Natalie4

Affiliation:

1. Johns Hopkins University, Baltimore, Maryland, USA

2. Bristol Myers Squibb, San Diego, California, USA

3. TB Alliance, New York, New York, USA

4. Bristol Myers Squibb, Global Health, San Diego, California, USA

Abstract

Efforts to develop more effective and shorter-course therapies for tuberculosis have included a focus on host-directed therapy (HDT). The goal of HDT is to modulate the host response to infection, thereby improving immune defenses to reduce the duration of antibacterial therapy and/or the amount of lung damage.

Funder

Bill and Melinda Gates Foundation

Bundesministerium für Bildung und Forschung

Department of Foreign Affairs and Trade, Australian Government

Foreign and Commonwealth Office

Irish Aid

Ministerie van Buitenlandse Zaken

United States Agency for International Development

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3